Abstract

The research aimed to assess how sacubitril/valsartan altered the early recurrence of paroxysmal atrial fibrillation after radiofrequency catheter ablation. A total of 100 patients with paroxysmal atrial fibrillation and cardiac insufficiency admitted to the cardiology department, Jingzhou Central Hospital, between September 2019 and October 2021, were randomized to experimental (n=54) and control (n=46) groups. Following treatment with radiofrequency catheter ablation, postoperatively, the control group was given perindopril tert-butylamine and the experimental group were provided with sacubitril/valsartan. Clinical characteristics such as age, gender, body mass index, blood lipids, hypertension, diabetes, coronary heart disease history, stroke, smoking and drinking status, were preoperatively gathered. Each patient’s N-terminal pro B-type natriuretic peptide test, dynamic electrocardiogram and transthoracic echocardiogram were examined before the surgical procedure, 1 mo after surgery, and 3 mo after surgery. Echocardiogram was used to assess the left ventricular end-diastolic diameter, the left ventricular ejection fraction, as well as the left atrium anteroposterior diameter. Dynamic electrocardiogram mainly assessed the presence or absence of recurrence of atrial fibrillation. The two groups were compared for preoperative and postoperative states of N-terminal pro B-type natriuretic peptide, left ventricular end-diastolic diameter, left ventricular ejection percent, left atrial anteroposterior diameter, adverse events, and drug withdrawal. Both groups received treatment for 3 mo. The experimental group seemed to have a 9.26 % early recurrence rate, while the control group had a 23.91 % early recurrence rate, with significant difference between the groups (p<0.05). The values of N-terminal pro B-type natriuretic peptide, left ventricular end-diastolic diameter, left atrium anteroposterior diameter, and left ventricular ejection fraction of the two groups showed a downward trend in both groups, with the difference between the test group was significant (p<0.05). There was no significant difference in adverse reactions and drug withdrawal between the two groups of patients after radiofrequency ablation (p>0.05). The combination of sacubitril/valsartan can reduce the early recurrence rate after radiofrequency catheter ablation of paroxysmal atrial fibrillation, improve the structure/function of the heart, thus leading to effective treatment and reduced recurrence rate.